NOVEMBER 2022LIFE SCIENCES REVIEW6Clinical trials are part of clinical research that follow strict protocols to obtain data about new drug development's safety and efficacy, leading to its approval for market release. The APAC region is the most significant contributor accounting for more than fifty percent of global clinical trials. Over the forecast period of 2022-27, the size of the market is estimated to increase at a CAGR of 8.9 percent. Technological advancements and increased demand for innovative healthcare solutions are the main reasons for this market growth. Artificial intelligence and machine learning are being used predominantly to find potential candidates for drug trials. Also, the demand for innovative solutions has led numerous biopharmaceuticals to partner with academic research centers, especially for early clinical development. This has steered the shift of focus on developing solutions to treat rare and terminal diseases. Furthermore, emerging nations are more cost competitive than developed ones, further strengthening this argument. In this edition of Life Sciences Review, we present you with the list of the top ten clinical-stage biopharmaceutical companies in the APAC market space which are at the forefront of innovation in the region's clinical-stage biopharmaceutical arena. Stewart Campbell, VP & General Manager, West AP and Li Chen, VP & General Manager, West Biologics, have shared their viewpoints to Life Sciences Review APAC on the various aspects of the industry. Additionally, companies like Accro Bioscience, Adagene, and Forest Hill Labs, with their top-notch R&D and solutions are opening doors to new possibilities in the clinical-stage biopharmaceutical sector. Life Sciences Review APAC also presents you with exclusive insights and thought pieces from expert CIOs and CXOs - Chris Braithwaite, SVP and Global Head of Drug Development Technology at Novartis, Hua Gong, M.D., Ph.D., SVP, Global Head of Translational Medicine and Clinical Biomarker, Zai Lab, discussing and providing their ideas on the trends currently practiced in the industry. We hope these valuable insights from industry leaders and solutions from leading solution providers featured in this edition will assist you in making informed decisions for your businesses. EDITORIALInfluence of Technological Advancements in Clinical-stage BiopharmaceuticalsCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsNovember - 21 - 2022, Vol 03, Issue - 05 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >